Serum visfatin in chronic renal failure patients on maintenance hemodialysis: A correlation study

Citation metadata

Date: October-December 2013
Publisher: Medknow Publications and Media Pvt. Ltd.
Document Type: Report
Length: 3,922 words
Lexile Measure: 1470L

Document controls

Main content

Article Preview :

Byline: Abdel Wahab. Lotfy, Nagwa. Mohammed, Hanan. El-Tokhy, Fatma. Attia

Background and aim of work Endothelial dysfunction, atherosclerosis, and cardiovascular disease are strongly linked to chronic kidney disease. It has been hypothesized that visfatin may play an important role in uremia-related atherosclerosis and the relation between visfatin and endothelial dysfunction has been proved. We aimed to study and characterize the relation of visfatin to some clinical and biochemical parameters among chronic renal failure (CRF) patients on regular hemodialysis. Patients and methods This study was carried out on a total of 90 individuals, divided into two groups: group A included 68 patients with CRF on regular hemodialysis (44 men and 24 women) and group B included 22 healthy individuals as controls (four men and 18 women). All participants were subjected to the following: full clinical assessment, BMI assessment, FBS (Fasting blood sugar), PPBS (postprandial blood sugar), Hb level, lipid profile, serum urea, creatinine, potassium, phosphorus, and serum visfatin. Results Serum visfatin concentration was significantly high in group A (uremic on hemodialysis) compared with group B (control) (48.95 ng/ml [+ or -]11.62 compared with 22.65 ng/ml [+ or -] 5.24; P < 0.001); a highly significant positive correlation was found between serum visfatin and serum low-density lipoprotein (r = 0.39; P < 0.001) and a significant positive correlation between serum visfatin and serum triglycerides and serum uric acid (r = 0.28; P < 0.05 and r = &#8722;0.24; P < 0.05), respectively, whereas a highly significant negative correlation between serum visfatin and Hb (r = &#8722;0.43; P < 0.001) and a significant negative correlation between serum visfatin and serum urea (r = &#8722;0.25; P < 0.05), blood sugar, both fasting and postprandial (r = &#8722;0.34; P < 0.001 and r = &#8722;0.39; P < 0.001), respectively, were found in the patients in group A, without a significant correlation either to high-density lipoprotein, serum creatinine, the etiology of CRF, or to the duration of dialysis in the patients in group A. Conclusion This study proves the association of serum visfatin with CRF, unrelated to the biochemical parameter of kidney functions; however, further studies to examine visfatin expression within renal tissue may clarify its definitive role in CRF.

Introduction

Intense research has been carried out in recent years on the pathophysiology of adipokines in renal disease and their relationship with the risk of cardiovascular disease in patients with renal failure. The direct association between some proinflammatory cytokines and cardiovascular morbidity and mortality seems clear, but the pathophysiological role and potential implications of other adipokines, such as visfatin, remain unclear [sup][1] .

Visfatin is an adipokine identified in 2004 and thus named for the suggestion that it would be predominantly produced and secreted in visceral fat [sup][2] . It has a molecular weight of 52 kDa and its gene encodes 491 amino acids. It is identical to pre-B cell colony-enhancing factor, described in 1994 as a cytokine produced by lymphocytes, acting on lymphocyte maturation and inflammatory regulation. Visfatin was also recognized recently as the formerly...

Source Citation

Source Citation   

Gale Document Number: GALE|A394270043